Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.51 |
| ▸ | PPARA | Q07869 | 13/20 | 0.51 |
| ▸ | PPARD | Q03181 | 3/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009876 | 0.95 | ADRB3 (0.56) | PPARGPPARAPPARDADRB3KDM4E | |
| SCHEMBL1010612 | 0.92 | PPARA (0.56) | PPARGPPARAPPARDADRB3 | |
| SCHEMBL1010866 | 0.90 | ADRB3 (0.52) | PPARGPPARAPPARDADRB3KDM4E | |
| SCHEMBL1011109 | 0.89 | PPARA (0.50) | PPARGPPARAPPARDADRB3KDM4E | |
| SCHEMBL1010640 | 0.87 | PPARG (0.40) | PPARGPPARAPPARDADRB3KDM4E | |
| SCHEMBL1009685 | 0.86 | PPARG (0.54) | PPARGPPARAPPARDADRB3KDM4E | |
| SCHEMBL1009671 | 0.84 | PPARA (0.47) | PPARGPPARAPPARDADRB3KDM4E | |
| SCHEMBL6543024 | 0.84 | PPARA (0.49) | PPARGPPARAPPARDADRB3KDM4E | |
| SCHEMBL1009638 | 0.84 | PPARG (0.50) | PPARGPPARAPPARDADRB3KDM4E | |
| SCHEMBL1010703 | 0.84 | PPARG (0.39) | PPARGPPARAPPARDADRB3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1661890-B1 | PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | KOWA CO (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-7183295-B2 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7109226-B2 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2006-09-19 | — | — | US | disclosed |
| US-20060189667-A1 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1661890-A1 | PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Kowa Co., Ltd. (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-20050101636-A1 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189667-A1 | PPAR-activating compound and pharmaceutical composition comprising the compound | PPARA, PPARG, PPARD | PPARG 2/4885PPARA 1/4885PPARD 3/4885 |
| US-20050101636-A1 | PPAR-activating compound and pharmaceutical composition comprising the compound | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.